



**Cancer  
Society**

Te Kāhui Matepukupuku  
o Aotearoa

Cancer Society  
Of New Zealand Inc.

Annual Report

**2017**



# CONTENTS

President's Report	02
Chief Executive's Report	04
Advocacy	06
Health Promotion	10
Research	11
Supporting People	16
Celebrating 50 years of Driving Service	18
Fundraising	19
Our People	22
Structure and Governance Statement	24
Elected Officers and Staff	26
Financial Summary	29
Auditor's Report	31



# PRESIDENT'S REPORT

It has been a year of rewarding work for the Cancer Society of New Zealand. Demand for our services out in the Divisions is continuing to grow, and you will read in this report that over the past year there have been a number of high-profile national issues that have required rigorous advocacy, both behind the scenes, in the media and with the community. It shows the strength of our federation right across the country that we have not only met these challenges, but thrived. And National Office has played a crucial role in this success.





This year, the National Board completed a comprehensive review of National Office with the goal of evaluating its strategic priorities and capacity. With this clearer picture, the Board are now firmly focused on the future strategy for the organisation, in consultation with the Divisions, whose work National Office supports.

To further develop the good work being done by National Office and the Divisions, the Board is advocating for a joint conference of directors, management, staff and volunteers from across our federation. Its emphasis will be on our ever-changing world and the impact that this will have on cancer treatment, research and, therefore, the Cancer Society's services.

In January this year, we bid Claire Austin farewell as she stepped down from her role as CEO to pursue other opportunities. Claire joined us in 2014 and under her leadership, National Office further developed its reputation as an advocate and expert voice on cancer, often entering into national debates on issues such as drug funding for melanoma patients and working with the Ministry of Social Development to cut red tape. I thank Claire for her contribution to the Cancer Society, and wish her well in her future endeavours.

Mike Kernaghan, already a well-known face from around the organisation, has since stepped into this leadership role. Mike was previously CEO of our Otago-Southland Division for six years before joining National Office in 2016 to provide strategic advice. He knows the ropes and the National Office team, and has built solid relationships across our federation and beyond. Mike's experience in leading a Division has given him a strong understanding of their work, as well as their requirements in terms of the support that National Office can provide. This will be an enormous asset. We are pleased to have him on board and look forward to working closely with him.

I would also like to thank my fellow Board Members, particularly our outgoing members, Simon Arcus and Kathy Conlan, for generously volunteering their time and expertise in governance.

A number of the National Board's committees also provide advice and expertise that guide our development of the Cancer Society's strategic direction. The Board is grateful for the assistance it receives from the members of the National Scientific Advisory Committee, the National Health Promotion Advisory Committee, the National Finance and Risk Advisory Committee and the National Executive Committee.

I also thank National Office, Divisional Staff and the Cancer Society's commercial company, Daffodil Enterprises Limited, for their exceptional work, commitment and energy. I am appreciative that so many are giving their time and knowledge to help their community.

Finally, I wish to thank our supporters - volunteers, donors and corporate partners, especially ANZ who are our Major Sponsor, Principal Sponsor of Daffodil Day and our Official Bank. They all help to make our work possible. The Cancer Society is committed to remaining at the forefront of cancer prevention, patient advocacy, medical research and support services, and your support is invaluable in helping us reach our goals. Thank you.

Sincerely,



Peter Hutchison,  
President of the Cancer Society's  
National Board

# CHIEF EXECUTIVE'S REPORT

This year the Cancer Society has continued to deliver outstanding results; in supporting those people impacted by cancer and supporting their whānau, in delivering key health promotion programmes to communities right across New Zealand, and in investing \$1.4 million dollars in research. We also advocated strongly, across a range of issues, to central and local government.



This couldn't be achieved without our staff and volunteers showing a level of commitment that is truly inspiring. We are incredibly fortunate to have highly skilled staff at National Office and Divisions who continue to make a difference every single day.

Our volunteers are an integral part of who we are and what we do; without their support, we simply couldn't achieve to the high levels that we do. 2017 marked the 50th anniversary of our volunteer driving service; each year our volunteer drivers cover 1 million kilometres transporting people to and from their treatment. There are literally thousands of volunteers who support the Cancer Society - whether that be within fundraising events such as Daffodil Day or Relay For Life, supporting our accommodation services, cooking meals or facilitating support groups. I thank you sincerely for your contribution.

Given 2017 is an election year, we have developed an election manifesto where we have identified key cancer issues that are impacting on our communities. Whilst this is covered in more detail elsewhere in this report, we have identified tobacco control, the National Travel Assistance Scheme (NTA), PHARMAC and bowel screening as being issues of key importance to New Zealanders.

The Cancer Society has continued to increase its presence in social media and in the media in general. We have focussed on a number of inequities facing New Zealanders with respect to access to timely and appropriate health care. My thanks to Dr. Chris Jackson, our Medical Director, for his eloquent and decisive advocacy.

To the National Board of the Cancer Society, we are indebted to your continued hard work on behalf of all of our members and to the guidance and support that you continue to show to staff at National Office. To all of the members of the National Scientific Advisory Committee, National Health Promotion Advisory Committee and to our National Finance Advisory Committee, thank you for your ongoing commitment to the Cancer Society. Your contribution is very important to the work of Divisions and National Office.

ANZ has once again been amazing in their support of the Cancer Society. As Major Sponsor of the Cancer Society, the ANZ bank and its staff right around the country contribute enormously to our success. To all of the ANZ staff, a sincere thank you for what you do.



Mike Kernaghan,  
Chief Executive of National Office





# ADVOCACY

---

In 2017, the Cancer Society has helped to influence some changes in legislation and government systems. The Cancer Society is a vocal and passionate advocate for reducing the incidence and impact of cancer, and this year we lobbied on a range of subjects that matter to Kiwis - from screening programmes that aim to detect cancers, to funding of treatments and more equitable care services that make life easier for patients. We highlight issues publically in the media, and also work constructively with government officials, ministers, the Government, opposition parties and other organisations to improve cancer outcomes.

As a non-profit organisation with no direct financial support from the government, we can independently inform and lobby, and our teams are dedicated to influencing positive change.

Here are some of our key projects from 2017.

## ADVOCATING FOR THE BOWEL SCREENING PROGRAMME

In the *Budget*, the Government announced a nationwide roll-out of bowel screening, which was a welcome result after some concentrated advocacy on our part. The scheme would be allocated a ring-fenced budget of \$100 million per annum in addition to the current pharmaceutical budget. It would also see PHARMAC investigate the costs and benefits of funding or not funding medicines.

## THE EMERGENCE OF E-CIGARETTES

The promotion and use of electronic cigarettes (or e-cigarettes) is contentious, and the evidence is still developing on how effective they are in helping people to quit smoking. Evidence is also still emerging on any long-term harm they may cause. More research is needed. We advise that the government approach e-cigarettes with caution, as we do not yet have a clear understanding of their possible impact.

## SUPPORTING FUNDING FOR BREAKTHROUGH MELANOMA THERAPIES

On 2nd August 2016, the Cancer Society was among those celebrating PHARMAC's decision to fund pembrolizumab (Keytruda), closely followed by nivolumab (Opdivo) for advanced melanoma. These are new immunotherapies that can help boost the body's natural defences to fight cancer. It was highly unusual for the Cancer Society to get involved in debates around the funding of particular cancer drugs. However, in this case we were moved to act for reasons of equity, evidence and deep concerns about availability for kiwis who could benefit. We couldn't be more thrilled that these new drugs are now available to New Zealanders. We will continue to lobby for an Early Access to Medicines Scheme, which if adopted, will mean that kiwis will have more timely access to drugs, like they do in other countries like the United Kingdom.



National Office's Chief Executive, Mike Kernaghan, giving a presentation at the Labour Party's Health Summit.





The Cancer Society's Medical Director, Dr. Chris Jackson, speaking with Health Select Committee Chairperson, National Party MP, Simon O'Connor.

## HELPING TO MAKE NATIONAL TRAVEL ASSISTANCE FAIRER

The Cancer Society has continued to advocate for changes to the National Travel Assistance Scheme to ensure that it is fair for all New Zealanders. The scheme provides financial assistance to people for whom the cost of travel and accommodation is a barrier to accessing treatment. We have met with government officials and opposition parties. Some of the patients we support have been on TV and in newspapers to outline their (not so great) experiences. So far, the Ministry of Health has acknowledged that the whole scheme needs to be reviewed, and the Cancer Society is awaiting an announcement on when this will happen. The Cancer Society will continue to advocate for changes in this area, and looks forward to working with the Ministry of Health to develop criteria that is equitable for all New Zealanders with cancer.

## CUTTING RED TAPE FOR CANCER PATIENTS RECEIVING FINANCIAL SUPPORT

One of the highlights of our year has been working with the Ministry of Social Development to improve Work and Income services for cancer patients. In the past, cancer patients were required to provide regular medical certificates in order to receive financial support while undergoing treatment. This added further stress at an already difficult time for cancer patients. Rightfully, the Ministry of Social Development has since scrapped the requirement, and now each patient's benefit will instead be tailored to fit their individual treatment programme timeframe. This change comes after some patients questioned the need to provide multiple certificates.

It's a great result and we commend the Government for the changes and would like to thank the Social Development Minister, Anne Tolley, for progressing this important work.





National Office's Chief Executive, Mike Kernaghan, being interviewed by TVNZ's Katie Bradford.

### LEGISLATING STANDARDISED PACKAGING OF TOBACCO PRODUCTS

Introducing standardised (plain) packaging for tobacco products had stalled in parliament since 2014, but was finally passed into law in September 2016. The Cancer Society sees this as one of many positive actions being taken to help New Zealand become smokefree by 2025. The Cancer Society also provided input into the proposed regulations to strengthen implementation.

Despite receiving petitions, submissions, and recommendations from the Health Select Committee, the Government has so far decided not to introduce any new legislation. Our work continues!

### PROTECTING OUR CHILDREN BY LOBBYING FOR SMOKEFREE CARS

We have been collaborating with a cross-organisational group who are leading a national push to make it illegal to smoke cigarettes in vehicles when there is an under 18 year old present. The purpose of this is to protect children from the harmful toxins in second-hand smoke. New Zealand research indicates that second-hand smoke in a car (even with the windows down) can be as bad as a smoky pub!

### SUBMISSIONS TO THE GOVERNMENT

We regularly make submissions to the government and other organisations advocating for what we believe is best practice.

Visit our website: [www.cancernz.org.nz](http://www.cancernz.org.nz) to read our submissions in full and learn how we're influencing change.





# HEALTH PROMOTION

We work to reduce the incidence of cancer in New Zealand through building strong partnerships and by advocating locally and nationally for evidence-based policy and legislation. We also support the development of healthy communities and settings.

The main areas we work on are:


**1** **Smokefree Aotearoa** | Achieving a Smokefree Aotearoa 2025

**2** **SunSmart Aotearoa** | Creating a SunSmart culture, and implementing the SunSmart Schools Programme

**3** **Healthy Aotearoa** | Addressing the level of obesity and alcohol-related cancers

**4** **Accessible Aotearoa** | Making cancer services easier to access for everyone, especially for Māori, Pacific, low-income & rural populations





---

Thanks to the generous support of our donors, the Cancer Society is able to invest significant sums of money into cancer-related research.

As an evidence-based organisation, research underpins all aspects of our work, from information and support services to health promotion, policy and advocacy. That's why every year we help to fund world-class research aimed at answering the big questions and reducing the impact and incidence of cancer.

Funded research has translated to evidence towards improvements in diagnosis and treatment. For example, some studies in the past five years identified fast-growing cancer subtypes that require aggressive treatment. The Cancer Society has also funded studies that

led to breakthroughs in immunotherapy. Immune therapies are now used to treat previously untreatable cancers, including types of melanoma skin cancer. Other research achievements include developing evidence to support wider use of drugs and radiation across cancer types. This aims to improve both quality of life and survival for people living with, through and beyond cancer.

Read on to find out how donations to the Cancer Society go towards cancer research.



## **FUNDING WORLD-CLASS RESEARCH BY THE CANCER SOCIETY SOCIAL AND BEHAVIOURAL RESEARCH UNIT (AWARDED \$392,500)**

---

A portion of our research fund goes towards supporting the Cancer Society Social and Behavioural Research Unit (CSSBRU), a relationship that has existed since 1990. The group's vision is to make a real difference to the well-being of others through their research.

There are a broad range of factors that affect the incidence and impact of cancer. Accordingly, the CSSBRU research programme covers a range of topics.

The unit has worked on many projects over the year:

### **TOBACCO CONTROL**

- “Tobacco and alcohol imagery on New Zealand television”
- “Smokers’ perceptions of the relative effectiveness of five retail reduction policies”
- “Tobacco control experts’ perceptions of tobacco retailing policies”
- “Discouragement of smoking among peers”
- “Local authority long-terms plans and Smokefree 2025”
- “Smokers’ attitudes towards financial incentives for quitting”
- “Quitting and tobacco retailer density”
- “Does quitting smoking lead to less binge drinking?”
- “Supporting informed e-cigarette use: a qualitative analysis”

### **SUN PROTECTION AND ULTRAVIOLET (UV) RADIATION-RELATED STUDIES**

- “Skin cancer primary prevention in New Zealand public secondary schools”
- “Quantifying the association between sun exposure and vitamin D status”
- “Sunburn in a New Zealand urban population, 1994-2006”
- “Systematic review of interventions for the primary prevention of skin cancer”
- “Systematic review of interventions for the primary prevention of skin cancer - update”
- “Adolescent sports events: an observational study”
- “Reducing harm from commercial sunbeds: Submission to the Ministry of Health”
- “Appearance-based intervention in secondary schools”
- “Using wearable cameras to obtain data on the sun-protective behaviours of primary school children and characteristics of school environments”



#### CANCER AWARENESS AND INFORMATION PROVISION

- “Changes in awareness of cancer risk factors among adult New Zealanders: 2001 to 2015”
- “Changes in awareness of risk factors for lung, bowel, melanoma, breast, cervical and prostate cancer among adult New Zealanders: 2001 to 2015”
- “Cancer-information seeking among adult New Zealanders: a national cross-sectional study”
- “New Zealand adults’ awareness of the Cancer Society of New Zealand’s services”
- “Changing perceptions of cancer mortality, early detection and treatment among adult New Zealanders between 2001 and 2014/5”
- “What helps you get through a diagnosis of cancer - a cross-sectional study of New Zealand adults”
- “New Zealand media reports about cancer and cancer perceptions among New Zealand adults”
- “Qualitative analysis of New Zealand media’s coverage of melanoma, non-melanoma and sun-safe behaviours during spring 2016”

#### ALCOHOL

- “Evaluation of New Zealand’s alcohol laws”

#### PSYCHO-SOCIAL-SPIRITUAL CANCER RESEARCH

- “New Zealand nurses’ views on spirituality and spiritual care”
- “MidCentral District Health Board Spiritual Care Advisory Group: a qualitative study”

## RESEARCH GRANTS AND TRAINING SCHOLARSHIPS

The Cancer Society is the largest non-government funder of cancer research in New Zealand through our annual Research Grants Programme. We also fund training scholarships to allow students to undertake advanced cancer research. This year we funded the following projects.

### JOHANNA PERRY FROM AUCKLAND UNIVERSITY (AWARDED \$100,005)

Skin cancer rates are very high in New Zealand and so having effective treatment options is important. Melanoma is one type of skin cancer that can be treated with immune therapies. Immune therapies are effective for a proportion of patients with metastatic melanoma, and Johanna Perry's research explores a new approach for those people who are not helped by existing treatments. By targeting growth hormone signalling, which may be needed for some melanoma cells to grow, Johanna hopes to create a new type of treatment.

### BRIDGET STOCKER FROM VICTORIA UNIVERSITY OF WELLINGTON (AWARDED \$186,550)

The past few decades have seen rapid advancements in immune therapies for treating cancer. Immune therapies work by increasing the ability of immune cells to destroy tumours. This research explores the role of specific molecules in tumour destruction by the immune system.

### MICHAEL ECCLES FROM THE UNIVERSITY OF OTAGO (AWARDED \$191,353)

New Zealand has more than 2,000 cases of melanoma a year, and each year more than 300 New Zealanders die of the disease. Once melanoma has spread beyond skin cells, it has limited treatment options. This project will identify specific epigenetic changes in melanoma cells that are reversed by treatment with the drug GSK126. In future, this research may help us find even better cancer treatments.

### ROSLYN KEMP FROM OTAGO UNIVERSITY (AWARDED \$80,000)

Cells in the body's immune system can kill cancer cells. The interaction between cancer cells and immune cells can predict outcomes from cancer treatment. Roslyn Kemp's research will investigate the composition of immune cells in mouse colorectal tumours and measure protection against tumour growth using a new vaccine delivery system.

### MIKE BERRIDGE FROM THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (AWARDED \$305,437)

Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options and a poor prognosis (future outlook). Mike Berridge's research explores the role of mitochondrial DNA in tumour cell function. We hope this research will help us to better understand how GBM tumours form and regrow using normal brain cells to stop existing radiation treatments.

### CHERIE BLENKIRON FROM THE UNIVERSITY OF AUCKLAND (AWARDED \$80,000)

Merkel Cell Carcinoma (MCC) is a type of skin cancer that is on the rise. Cherie Blenkiron's research will explore mutations in the MCC cell DNA to better understand how they form, grow and spread. A clearer understanding of these cancers in New Zealand will allow our doctors to treat patients in a more directed manner and improve understanding and health outcomes for all.

## TRAINING SCHOLARSHIPS

### TAMATI PENI, UNIVERSITY OF WAIKATO

*Improving supportive care for high needs women and whānau with breast cancer.*

### MICHELLE EDWARDS, UNIVERSITY OF AUCKLAND

*The effects of multimorbidity on breast cancer outcomes in New Zealand.*



# INTERNATIONAL STUDY LOOKS AT CANCER SURVIVORSHIP

---



## **WHY DO SOME COUNTRIES HAVE BETTER CANCER SURVIVAL RATES THAN OTHERS? WHAT CAN WE LEARN FROM THIS?**

These are some of the questions that a landmark new project is exploring, and the Cancer Society is proud to be taking part.

This year the Cancer Society submitted its first set of data to the International Cancer Benchmarking Project, which is led by the World Health Organisation. It is the first collaboration of its kind seeking to not only identify international differences in cancer survival, but also to explore things that might influence those differences.

The project has a number of parts, and the Cancer Society participated in what is called the SURVMARK-2 project. Its purpose is to produce data on cancer survival, incidence and mortality from across seven high-income countries.

Learn more about how we're supporting cancer research, visit: [www.cancernz.org.nz](http://www.cancernz.org.nz)



# SUPPORTING PEOPLE

---

Over the past year, we've continued to deliver care and support to people affected by cancer, including practical assistance, emotional support, education and advocacy. National Office was proud to assist the Divisions administering this.

## NATIONAL STATISTICS

**9,720** 

calls answered by the Cancer Society's Cancer Information Helpline last year.

**62,395** 

bed nights at our accommodation, close to hospitals.

**1,131,191** 

kilometres were driven by volunteer drivers taking patients to their treatment –

*That's* **19,634** *trips helping* **2,826** *patients!*

## WHY WE'RE FOCUSING ON CANCER SURVIVORSHIP

These days more and more people are living with and beyond cancer, which is good news as it demonstrates improvements in treatment and outcomes. However, for many people the impact of cancer is still being felt after treatment ends. To address this, the Cancer Society has been working on understanding and supporting the needs of our changing cancer population.

National Office, in conjunction with Cancer Society Divisions, has been working with the Central Cancer Network and Cancer Nurses College to develop a nationally consistent approach to the principles, language and pathways for people affected by cancer.

This work included a national workshop with health professionals and organisations that identified a need for:

1. survivorship care planning from diagnosis - with the patient at its centre
2. coordinated services - during and after treatment
3. workforce requirements to support survivorship
4. making cancer services easier to access for everyone, and providing culturally-appropriate support.

We look forward to continuing our work with the sector in 2018.

## HELPING UNDERSTANDING THROUGH OUR CANCER INFORMATION

In an age where cancer publications are everywhere, the Cancer Society stands out as a trusted source of health information for New Zealanders. Our popular range of resources offer plain-English, evidence-based information on everything from cancer types and treatments, to living with cancer.

You can read our publications by visiting our website: [www.cancernz.org.nz](http://www.cancernz.org.nz). You can also receive copies by phoning the Cancer Information Helpline **0800 CANCER (226 237)**, or by contacting your local Cancer Society.



Some of the new editions published this year.



# CELEBRATING 50 YEARS OF DRIVING SERVICE

---

50

**FIFTY YEARS AGO IN THE CAPITAL, THE WHEELS BEGAN TURNING ON A FREE SERVICE FOR CANCER PATIENTS NEEDING TRANSPORT TO TREATMENT.**



Advances in radiation treatment meant regular hospital visits for patients - often over many months. The demand was so great, the service spread nationwide and today operates in all six of the Cancer Society's divisions.

Over 1,000 volunteers provide the service free of charge, giving up their own time and cars for the benefit of cancer patients. The volunteers deal with long travel times, peak traffic, all kinds of weather and are sometimes away from home for up to 10 hours. Being a driver can be stressful and requires a great deal of attention to both the patient's needs and the road to ensure the patient reaches their treatment safely and on time.

It's because of the volunteer drivers that many patients are able to receive their treatment. Thank you to all our wonderful volunteers for keeping the service going for so long.



# FUNDRAISING

As an independent charity, fundraising is crucial in helping fund our services, and we are proud to be regarded as one of New Zealand's most valued charities. We are sincerely grateful to everyone who chose to donate and support our cause during this past financial year.

## ACKNOWLEDGMENTS

Major Sponsor of the Cancer Society,  
Principal Sponsor of Daffodil Day and Official Bank



## OTHER NATIONAL SUPPORTERS

- Fuji Xerox
- Eftpos New Zealand
- Signature Promotions

## PAYROLL GIVING

---

The Cancer Society is recognised by the IRD as an approved donee organisation, so can receive donations by way of payroll giving. The Cancer Society has been nominated by a number of organisations to receive donations from payroll giving, which provide a tax credit of 33 1/3 per cent on the total deduction.

The Cancer Society sincerely appreciates the valuable support it has received from participating organisations and their employees, which includes, but is not limited to:

- AHL Group
- Department of Internal Affairs
- iPayroll
- Inland Revenue Department
- Ministry of Social Development
- Rabobank
- Spark Foundation
- The Warehouse
- Event Cinemas LH
- Rydges Hotels
- Hotel Management Group
- Ministry of Education
- New Bay Investment
- Chartered Accountants Australia & New Zealand
- Noel Leeming

## NATIONAL FUNDRAISING EVENTS

---

### DAFFODIL DAY

One of the biggest events in the Cancer Society's calendar is our annual Daffodil Day appeal, which calls on the amazing support of volunteers, staff and donors. Daffodil Day is one of the largest generator of funds for the Cancer Society, and the money we receive goes towards funding our many services within communities.

Daffodil Day in numbers:

- \$4.6 million raised
- 11,000 volunteers on the streets
- 1,341 collection sites across the country
- Thousands of local businesses collecting donations
- 27 years of support from our Principal Sponsor, ANZ
- Over \$1 million raised by ANZ.

A highlight of Daffodil Day was the contribution of our Principal Sponsor, ANZ, who again raised over \$1 million dollars for us this year. Their contribution came in the form of direct sponsorship, money collected via their branches and the efforts of passionate ANZ staff who fundraise in their communities.



## BEQUESTS

---

Bequests are a vital source of philanthropic support, and we appreciate the kindness and forethought of our donors. The Cancer Society has an active bequest programme, and it welcomes the opportunity to honour supporters during their lifetime while they are able to accept our thanks and appreciation. Bequests go directly to Divisions, and help fund local support as well as national advocacy, information and research.

## PLEASE DONATE - WITH YOUR HELP THERE IS HOPE

Everyone living with cancer deserves support for themselves and their families, and your support will help ensure they don't face cancer alone. Please consider how you can support the Cancer Society:

- Donate by mail, text, direct deposit into a Cancer Society bank account, in person, or through our website: [www.cancernz.org.nz](http://www.cancernz.org.nz)
- Encourage your employer to make a tax-deductible donation
- Support our fundraising events or organise your own
- Make a bequest in your will
- Make a regular donation in conjunction with a workplace payroll giving scheme
- Become a sponsor.

To find out more, visit our website: [www.cancernz.org.nz](http://www.cancernz.org.nz)

## RELAY FOR LIFE

Relay For Life is an inspiring community event that gives everyone a chance to celebrate cancer survivors and carers, remember loved ones lost to cancer, and fight back. Relay enables the Cancer Society's Divisions to increase their engagement with their communities and raise awareness and funds to support our work.

Relay For Life in numbers:

- Relays were held in 17 different communities
- 823 teams took part (that's 13,542 team members!)
- 3,119 survivors and carers took part across 17 events
- Just over \$2.3 million was raised
- Otago University Relay raised over \$101,000.

To keep providing the best experience for our volunteers and relayers, we worked on two big national projects in 2017. The first was a summit, held in Wellington, to share ideas and experience between 35 staff and volunteers from across the country. The summit looked at how we can continue to reach out and build community engagement, as well as increase our fundraising.

Our second achievement was the launch of the new Relay website: [www.relayforlife.org.nz](http://www.relayforlife.org.nz). The new design has been a hit - the amount raised online (as part of the total amount raised) has increased from 38 per cent in 2016 to 44 per cent in 2017.

The Cancer Society was also proud to be beneficiary of another national fundraising event in 2017: **Shitbox Rally New Zealand**.

Next year, we'll do this all again, and we'd love your support.



## OUR PEOPLE

---

**Top left:**

Hypatia Stacy-Baynes, Leigh Taggart, Hazem Abd Elkader, Shayne Nahu and Helga Wientjes.

**Middle:**

Dr. Rachel Nicholls, Melanie Metuariki, Daniel Glover, Louise Sandford and Ashten Macdonald.

**Front:**

Vicky Shuker, Janine Neal, Annita Patel and Heather Knewstubb.

**Not pictured:**

Mike Kernaghan and Hohepa MacDougall.

# NATIONAL BOARD OF THE CANCER SOCIETY OF NEW ZEALAND



Peter Hutchison



Mike Kernaghan



Alister Argyle



Jonathan Koea



Neil Boniface



Murray Loewenthal



Kathy Conlan




Kate Morrison



Dr. Garry Forgeson



Michael Smith



Dr. Chris Jackson

Stuart Bauld (absent)





# STRUCTURE AND GOVERNANCE STATEMENT

---

## ORIGINS

The Cancer Society of New Zealand was incorporated in 1963.

## ORGANISATIONAL STRUCTURE      GOVERNANCE STRUCTURE

The Cancer Society is a federation of seven organisations and sixteen centres. Its seven organisations are: National Office, Auckland and Northland, Waikato/Bay of Plenty, Central Districts (Taranaki, Wanganui, Gisborne, Hawkes Bay and Manawatu), Wellington (including Nelson and Marlborough), Canterbury-West Coast and Otago and Southland. Core areas of activity are carried out by all Divisions, and each Division fulfils its local role to address its community's needs.

The six Divisions appoint a National Board, which comprises a representative from each Division, as well as a President to govern the Cancer Society of New Zealand. The Chair of the National Finance Audit and Risk Advisory Committee is present on the Board as a voting member. The Chair of the National Executive Committee and the Chief Executive of National Office attend in an ex officio capacity. All Board members are volunteers.

## OUR VISION

The leading organisation dedicated to reducing the incidence of cancer and ensuring the best cancer care for New Zealanders.

## MISSION STATEMENT

Improving community well-being by reducing the incidence and impact of cancer. This is achieved through the provision of health promotion, support services, information and research.

### THE ROLE OF THE CANCER SOCIETY NATIONAL OFFICE

The Cancer Society's National Office exists to promote and advocate for agreed policy goals, provide expert advice and optimise the Cancer Society's research programme. It acts as an information conduit, supporting Divisions with the provision and exchange of information, innovation and best practice. It works to support and strengthen the sustainability of Divisions and maximise their services. The Cancer Society's National Office also coordinates activities that can best be done on a national basis. This work is headed by the Chief Executive.

National Advisory Committees operate in the areas of finance, health promotion and research. The committees work closely with National Office staff to provide expert advice to the Cancer Society National Board.

The National Executive Committee also acts as an Advisory Committee to the Board.

Assessment of applications for research grants is undertaken by the National Scientific Committee in order to provide independent rigour to decision making.

### FUNDING

The Cancer Society receives no direct government funding. Core services and operational responsibilities are funded by division levies, which are calculated on a population basis. The Divisions' main source of income is from donations from the public. Administration revenue is also supplemented by income from a small investment portfolio and from royalties and dividends from Daffodil Enterprises Limited, the Cancer Society's wholly owned trading company.

### SPONSORSHIP

ANZ bank provides tremendous support through its sponsorship of the Cancer Society and the fundraising efforts of its staff. We are very grateful to ANZ, who is Major Sponsor of our organisation, Principal Sponsor of Daffodil Day and the Official Bank of the Cancer Society.

### FINANCIAL REPORTING

The financial statements in this report reflect the activities of the Cancer Society's National Office only. The Divisions, being autonomous organisations, publish their own independent financial statements.



# ELECTED OFFICERS AND STAFF

---

## NATIONAL BOARD MEMBERS

### President

Mr. Peter Hutchison

### Auckland Northland Division

Mr. Jonathan Koea

### Waikato/Bay of Plenty Division

Mr. Murray Loewenthal

### Central Districts Division

Dr. Garry Forgeson

### Wellington Division

Mr. Simon Arcus (to June 2017)

Ms. Kate Morrison (from June 2017)

### Canterbury-West Coast Division

Ms. Kathy Conlan (to April 2017)

Mr. Alister Argyle (from April 2017)

### Otago and Southland Division

Mr. Neil Boniface

### Medical Director

Dr. Chris Jackson

### National Finance, Audit and Risk Advisory Committee Chair

Mr. Stuart Bauld



## **NATIONAL BOARD EX OFFICIO**

Mr. Michael Smith  
(National Executives' Committee Chair)

Mr. Mike Kernaghan  
(Chief Executive, National Office)

---

## **NATIONAL HEALTH PROMOTION ADVISORY COMMITTEE CHAIR**

To be confirmed

## **NATIONAL SCIENTIFIC ADVISORY COMMITTEE CHAIR**

Prof. Brett Delahunt

---

## **PAST PRESIDENTS**

Sir James Elliott 1925-1955

Dr. P. Lynch 1956-1957

Mr. L. A. Bennett 1958-1959

Prof. Eric D'Ath 1960-1961

Mr. J. Maxwell Clarke 1962-1963

Mr. R. O'Regan 1964-1965

Mr. J. K. Davidson 1966-1968

Mr. H. Gaudin 1967-1970

Mr. J. M. Tyler 1971-1972

Mr. C. T. Collins 1973-1974

Mr. Arthur Ibbotson 1975-1976

Mr. G. W. Holland 1977-1978

Mr. E. Gifford 1979-1980

Dr. D. W. Urquhart 1981-1982

Mr. B. Prior 1983-1984

Mr. John Heslop 1985-1986

Dr. P. R. Kelleher 1987-1988

Mr. Don Carnachan 1989-1990

Dr. Chris Atkinson 1991-1994

Prof. John Blennerhassett 1995-1996

Mr. John Kelly 1997-2000

Dr. David Perez 2001-2002

Mr. Richard Gray 2003-2006

Mr. Russell McIlroy 2007-2010

Mr. Clive Clelland 2010-2013

Mr. Murray MacCormick 2013-2015

## **MERITORIOUS AWARD RECIPIENTS**

Mr. William Kelso

Dr. David Perez

Dr. Peter Fitzgerald

Dr. David Becroft

Assoc Prof. Chris Atkinson

Mr. Athol Hutton

Mr. Anthony Finnegan

Mr. Tony Schramm

Mr. Geoff Clatworthy

Mr. Carrick Davidson

Mr. Richard Gray

Mr. Brian Tyler

Ms. Kate Reid

Dr. Simon Allan

Mr. Russell McIlroy

Prof. Brett Delahunt

## **PATRON**

Her Majesty Queen Elizabeth II

---

## **LIFE MEMBERS**

Mr. B. C. Prior  
Prof. John Gavin  
Mr. John Heslop  
Dr. Pat Kelleher  
Dr. Alan Gray  
Prof. B. Heslop  
Dr. Peter Fitzgerald

---

## **AUDITORS**

BDO Wellington  
50 Customhouse Quay, Wellington

## **BANKERS**

ANZ  
PO Box 2846, Wellington

---

## **NATIONAL OFFICE STAFF**

**Chief Executive**  
Mike Kernaghan

**Kaumatua**  
Hohepa MacDougall

**Communications and Marketing Manager**  
Daniel Glover

**Communications Officer**  
Hypatia Stacy-Baynes

**Media Advisor**  
Ashten Macdonald

**Capacity and Development Manager**  
Helga Wientjes

**National Projects Support Officer**  
Annita Patel

**Policy and Research Manager**  
Louise Sandford

---

## **DAFFODIL ENTERPRISES LTD**

**General Manager**  
Fiona Mawley

## **SOLICITORS**

Kensington Swan  
89 The Terrace, Wellington

**Policy Analyst**  
Hazem Abd Elkader

**Senior Supportive Care Advisor**  
Vicky Shuker

**Health Promotion and Campaigns Manager**  
Shayne Nahu

**Health Promotion Advisor**  
Dr. Rachel Nicholls

**Health Promotion Advisor**  
Heather Knewstubb

**Accountant**  
Leigh Taggart

**Assistant Accountant**  
Janine Neal

**Executive Officer, Board Secretary and Governance Support**  
Melanie Metuariki

**Corporate Support**  
Karen Ilton

# FINANCIAL SUMMARY

FINANCIAL SUMMARIES FOR THE YEAR ENDED 31 MARCH 2017

## SUMMARY STATEMENT OF COMPREHENSIVE REVENUE AND EXPENSE

	2017	2016
<b>Revenue from Non-Exchange Transactions</b>		
Bequests, Donations and Grants	335,663	979,673
Fundraising - Daffodil Day Donations	1,124,699	1,240,734
<b>Total Revenue from Non-Exchange Transactions</b>	<b>1,460,362</b>	<b>2,220,407</b>
<b>Revenue from Exchange Transactions</b>		
Divisional Levies	2,974,799	3,121,166
Royalties and Commission Income	701,662	540,337
Investment income	226,511	184,429
Other Revenue	107,140	122,847
<b>Total Revenue from Exchange Transactions</b>	<b>4,010,112</b>	<b>3,968,779</b>
<b>TOTAL REVENUE</b>	<b>5,470,474</b>	<b>6,189,186</b>
<b>Expenses</b>		
Fundraising - Daffodil Day Expenses	1,124,699	1,285,223
Operating Expenses	1,399,216	2,135,056
Personnel Costs	1,834,139	1,327,588
Research Commissions and Grants	1,402,654	1,702,135
<b>TOTAL EXPENSES</b>	<b>5,760,708</b>	<b>6,450,002</b>
<b>TOTAL DEFICIT</b>	<b>(290,234)</b>	<b>(260,816)</b>

## SUMMARY STATEMENT OF CHANGES IN NET ASSETS

	2017	2016
<b>Capital Reserve</b>		
Opening Balance	1,252,913	1,666,075
Comprehensive Revenue and Expenses for the year	(290,234)	(260,816)
Transfer out to Research Capital Reserve	(383,606)	(152,346)
<b>Total Capital Reserve</b>	<b>579,073</b>	<b>1,252,913</b>
<b>Research Capital Reserve</b>		
Opening Balance	3,148,628	3,221,930
Transfers in from Capital Reserve	383,606	152,346
Restatement of Scientific Research Grants Committed	(1)	(225,648)
<b>Total Research Capital Reserve</b>	<b>3,532,233</b>	<b>3,148,628</b>
<b>TOTAL EQUITY:</b>	<b>4,111,306</b>	<b>4,401,541</b>



## SUMMARY STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2017

	2017	2016
<b>Assets</b>		
Current Assets	1,363,543	1,787,817
Non-Current Assets	3,773,277	4,110,591
<b>Total Assets</b>	<b>5,136,820</b>	<b>5,898,408</b>
<b>Liabilities</b>		
Current Liabilities	430,189	522,698
Non-Current Liabilities	595,325	974,169
Equity	4,111,306	4,401,541
<b>Total Liabilities &amp; Equity</b>	<b>5,136,820</b>	<b>5,898,408</b>

## SUMMARY STATEMENT OF CASHFLOWS

FOR THE YEAR ENDED 31 MARCH 2017

	2017	2016
Net Cashflow from Operating Activities	(815,512)	(719,438)
Net Cashflow from Investing Activities	539,749	285,600
<b>Net Cash Flow</b>	<b>(275,763)</b>	<b>(433,838)</b>

## NOTES TO THE SUMMARY REPORT

The summary financial statements comprising of Cancer Society of New Zealand Incorporated and its controlled entity Daffodil Enterprises Limited, together the (“Group”) are presented for 2017. The information was extracted from the full financial statements as audited by BDO Wellington, who issued an unmodified opinion over the financial statements, and which were approved by the board on 14 August 2017. They cannot be expected to provide as complete an understanding as provided by the full financial report.

The full accounts are available on application to the Cancer Society of New Zealand Incorporated at PO Box 651, Wellington. The presentation currency is New Zealand dollars. All amounts are stated in \$’s.

## STATEMENT OF COMPLIANCE

The full Group Financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand (“NZ GAAP”). They comply with Public Benefit Entity International Public Sector Accounting Standards (“PBE IPSAS”) and other applicable financial reporting standards as appropriate that have been authorised for use by the External Reporting Board for Not for Profit entities. For the purposes of complying with NZ GAAP, the group is a public benefit Not for Profit entity and is eligible to apply to Tier 2 Not for Profit PBE IPSAS on the basis that it does not have public accountability and has between \$2m and \$30m operating expenditure.

The Board has elected to report in accordance with Tier 2 Not for Profit PBE Accounting Standards and in doing so has taken advantage of all applicable Reduced Disclosure Regime (“RDR”) disclosure concessions.

The summary financial statements have been prepared in accordance with FRS-43: Summary Financial Statements.

# AUDITOR'S REPORT

---

## REPORT OF THE INDEPENDENT AUDITOR ON THE SUMMARY FINANCIAL STATEMENTS To the members of Cancer Society of New Zealand Incorporated

### REPORT ON THE SUMMARY FINANCIAL REPORT

The summary financial statements, which comprise the summary statement of financial position as at 31 March 2017, the summary statement of comprehensive revenue and expense, summary statement of changes in net assets and summary statement of cashflows for the year then ended, and related notes, are derived from the audited consolidated financial statements of Cancer Society of New Zealand Incorporated for the year ended 31 March 2017.

In our opinion, the accompanying summary financial statements are consistent, in all material respects, with the audited consolidated financial statements, on the basis described in the Notes to the Summary Report.

### SUMMARY FINANCIAL STATEMENTS

The summary financial statements do not contain all the disclosures required by the Not-for-profit Public Benefit Entity Accounting Standards Reduced Disclosure Regime. Reading the summary financial statements and the auditor's report thereon, therefore, is not a substitute for reading the audited consolidated financial statements and the auditor's report thereon.

### THE AUDITED FINANCIAL STATEMENTS AND OUR REPORT THEREON

We expressed an unmodified audit opinion on the audited consolidated financial statements in our report dated 14 August 2017.

### DIRECTORS' RESPONSIBILITY FOR THE SUMMARY FINANCIAL STATEMENTS

Directors are responsible on behalf of the entity for the preparation of the summary financial statements on the basis described in the Notes to the Summary Report.

### AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on whether the summary financial statements are consistent, in all material respects, with the audited consolidated financial statements based on our procedures, which were conducted in accordance with International Standard on Auditing (New Zealand) (ISA (NZ)) 810 (Revised), Engagements to Report on Summary Financial Statements.

In addition to audit services, our firm provides other services in the areas of accounting and tax advice. Other than in these regards, we have no other relationship with or interests in Cancer Society of New Zealand Incorporated or any of its subsidiaries.

BDO WELLINGTON  
14 August 2017  
Wellington  
New Zealand



ISSN 2463-3224

# THANK YOU

We're proud of our achievements in 2017, but there's much more to do in the coming years. There is a growing demand for our services, and we need your support.

To donate, fundraise, volunteer or read information about cancer, visit our website:

[www.cancernz.org.nz](http://www.cancernz.org.nz)

or contact your local Cancer Society.





CANCER INFORMATION HELPLINE  
**0800 CANCER (226 237)**  
[www.cancernz.org.nz](http://www.cancernz.org.nz)

**NATIONAL OFFICE**  
Level 6 Ranchhod Tower, 39 The Terrace, Wellington  
PO Box 651, Wellington 6140  
Telephone: (04) 494 7270



**Major Sponsor**